Observational studyBMC nephrology2025
Prevalence, outcomes, costs, and treatments of a contemporary population with chronic kidney disease in Norway: a nationwide observational study.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Implementation gaps in contemporary heart failure therapy: a two-country nationwide analysis.Open heart · 2026Article
- Epidemiology of cardiovascular-kidney-metabolic syndrome.Nature reviews. Nephrology · 2026Review
- Impact of type 2 diabetes on the relationship between chronic kidney disease and cardiovascular outcomes in heart failure across ejection fraction: observational study from the Swedish heart failure and the Swedish National diabetes registries.Cardiovascular diabetology · 2025Observational
- Mind the Gap Between Estimated Needs and Current Resources in Chronic Kidney Disease.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis nation-wide study describes patients with diagnosed chronic kidney disease (CKD), with and without type 2 diabetes (T2D).
methodsPrevalence, key adverse outcomes, health care costs, and use of kidney-protective treatment, up until December 31st, 2022, were described in patients aged > 18 years in Norway using register-based data. Only diagnosis codes were used to identify patients with CKD, with laboratory measurements of estimated-glomerular filtration rate and albuminuria unavailable. Utilisation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and renin-angiotensin system [RAS] inhibitors were evaluated in new users following the first Norwegian approval of an SGLT-2 inhibitor for CKD treatment.
resultsApproximately 3% (125,163 patients) of adults in Norway had diagnosed CKD (average age 70 years, 42% women, 73% without T2D). When describing patients with or without T2D, history of heart failure (22% versus 22%), atherosclerotic cardiovascular disease (ASCVD; 57% versus 51%), and atrial fibrillation (24% versus 27%) were similar. Larger proportions of those with T2D received SGLT-2 inhibitors (24% versus 4%) and/or RAS inhibitors (63% versus 47%). Hospitalisations for CKD (28.1 versus 22.1 events per 100 patient years), heart failure (12.6 versus 9.8), myocardial infarction (3.9 versus 2.2), and stroke (3.2 versus 2.3) were more common in patients with CKD and T2D than those without T2D. However, mortality (10.8 versus 8.5) was higher in patients without T2D. CKD and heart failure costs were higher than those for ASCVD, and generally higher in patients with T2D. SGLT-2 inhibitor utilisation increased two-fold the year after its approval but was still low, used mostly at its highest target dose. Discontinuation rates were lower with SGLT-2 inhibitors than with RAS inhibitors, the latter mostly utilised at low doses.
conclusionsA CKD diagnosis was associated with substantial morbidity and mortality, costs, and undertreatment, both in patients with and without T2D. Use of novel kidney-protective treatment has increased, but an urgent need to improve the utilisation of kidney-protective medications remains, particularly in patients without T2D. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.